Account
Insider Insights
24.07.2023
Johnson & Johnson sue the US government

J&J sues US government, alleging infringement on First Amendment rights and unfair drug pricing unde...

Read more
Insider Insights
12.06.2023
CMS sets inflation penalties on 43 drugs

In a move towards curbing rising drug prices, the Inflation Reduction Act (IRA) provision will impos...

Read more
Newsletter
17.05.2023
PMA Insights: Week 20 SPECIAL EDITION – ISPO...

We summarise ISPOR Annual 2023 including plenary sessions on artificial intelligence, real-world evi...

Read more
Publications
09.05.2023
ISPOR US 2023: Plenary Session 1 – Global Fo...

Our experts provide a detailed summary of Plenary Session 1 at ISPOR Annual 2023 on global affordabi...

Read more
Insider Insights
09.03.2023
CMS declines to revise coverage for FDA-approved t...

CMS denies coverage of FDA-approved treatments that target amyloid for Alzheimer's disease unless th...

Read more
Insider Insights
06.03.2023
The Project Orbis initiative

The Project Orbis initiative is an international partnership between medicines regulators in the UK,...

Read more
Insider Insights
06.03.2023
Italy AIFA reports on manufacturer paybacks

Collectively, companies still owe AIFA €370 million of the €2.8 billion that industry has to rep...

Read more
Newsletter
17.02.2023
PMA Insights: Week 7

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Articles
17.02.2023
How will governments face the cost of medical mira...

Among the most expensive therapies are gene therapies that show promise to transform inherited disor...

Read more
Insider Insights
09.02.2023
New criteria for ATMPs which must follow quality r...

The Federal Joint Committee (G-BA) has set out criteria for ATMPs which are likely to require qualit...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.